{"id":10257,"date":"2025-11-28T21:33:25","date_gmt":"2025-11-28T18:33:25","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10257"},"modified":"2025-11-28T21:33:25","modified_gmt":"2025-11-28T18:33:25","slug":"kras-g12c-mutasyonu-ve-sotorasib-akciger-kanseri-tedavisinde-yeni-donem","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10257","title":{"rendered":"KRAS G12C Mutasyonu ve Sotorasib: Akci\u011fer Kanseri Tedavisinde Yeni D\u00f6nem"},"content":{"rendered":"<h2>KRAS G12C Mutasyonu Nedir ve Neden Akci\u011fer Kanseri \u0130\u00e7in Kritik?<\/h2>\n<p>\nAkci\u011fer kanseri tedavisinde y\u0131llarca \u201cila\u00e7lanamaz\u201d kabul edilen hedeflerin ba\u015f\u0131nda <strong>KRAS onkogenik mutasyonlar\u0131<\/strong> geliyordu. \u00d6zellikle sigara ile ili\u015fkili akci\u011fer adenokarsinomlar\u0131nda s\u0131k g\u00f6r\u00fclen <strong>KRAS G12C mutasyonu<\/strong>, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7larla se\u00e7ici bi\u00e7imde hedeflenemedi\u011fi i\u00e7in klinisyenler a\u00e7\u0131s\u0131ndan ciddi bir \u201ck\u00f6r nokta\u201d olu\u015fturuyordu.\n<\/p>\n<p>\nBu tabloyu de\u011fi\u015ftiren molek\u00fcllerden biri, ilk se\u00e7ici <strong>KRAS G12C inhibit\u00f6rlerinden<\/strong> olan <strong>sotorasib<\/strong> oldu. KRAS, h\u00fccre i\u00e7i sinyal iletiminde rol alan bir GTPaz proteini; G12C mutasyonu ise proteini s\u00fcrekli \u201ca\u00e7\u0131k\u201d konumda tutarak durmaks\u0131z\u0131n proliferasyon sinyali g\u00f6ndermesine neden oluyor. Sotorasib, KRAS G12C proteininin <strong>GDP ba\u011fl\u0131, inaktif konformasyonuna kovalent olarak ba\u011flanarak<\/strong> bu onkogenik sinyallemeyi bask\u0131l\u0131yor ve t\u00fcm\u00f6r b\u00fcy\u00fcmesini yava\u015flat\u0131yor veya durdurabiliyor<br \/>\n<a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1917239\">doi:10.1056\/NEJMoa1917239<\/a>.\n<\/p>\n<h2>Sotorasib Nas\u0131l \u00c7al\u0131\u015f\u0131r? K\u00fc\u00e7\u00fck Molek\u00fcl\u00fcn B\u00fcy\u00fck Mekanizmas\u0131<\/h2>\n<p>\nSotorasib, a\u011f\u0131zdan kullan\u0131lan, k\u00fc\u00e7\u00fck molek\u00fcl yap\u0131s\u0131nda, y\u00fcksek se\u00e7icili\u011fe sahip bir <strong>KRAS G12C inhibit\u00f6r\u00fc<\/strong> olarak tasarland\u0131. Molek\u00fcl, KRAS proteininin \u201cswitch-II\u201d olarak adland\u0131r\u0131lan hidrofobik cebine yerle\u015fiyor ve mutant sistein (Cys12) ile <strong>kovalent ba\u011f<\/strong> olu\u015fturarak proteini kal\u0131c\u0131 bi\u00e7imde GDP-ba\u011fl\u0131, inaktif forma kilitliyor<br \/>\n<a href=\"https:\/\/doi.org\/10.1038\/s41586-020-3185-5\">doi:10.1038\/s41586-020-3185-5<\/a>.\n<\/p>\n<p>\nBu mekanizma sayesinde:\n<\/p>\n<ul>\n<li><strong>MAPK\/ERK yolu<\/strong> ba\u015fta olmak \u00fczere a\u015fa\u011f\u0131 ak\u0131m proliferatif sinyal yollar\u0131 bask\u0131lan\u0131yor,<\/li>\n<li>T\u00fcm\u00f6r h\u00fccrelerinin b\u00fcy\u00fcme ve b\u00f6l\u00fcnme kapasitesi azal\u0131yor,<\/li>\n<li>Vah\u015fi tip KRAS ve di\u011fer GTPazlar g\u00f6rece korunarak, daha hedefe y\u00f6nelik bir etki profili sa\u011flan\u0131yor.<\/li>\n<\/ul>\n<p>\nK\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131 a\u00e7\u0131s\u0131ndan bak\u0131ld\u0131\u011f\u0131nda sotorasib, \u201cila\u00e7lanamaz\u201d kabul edilen bir hedefin asl\u0131nda <strong>dinamik konformasyonel cepleri<\/strong> kullan\u0131larak nas\u0131l hedeflenebilece\u011fine dair \u00e7arp\u0131c\u0131 bir \u00f6rnek sunuyor.\n<\/p>\n<h2>Klinik \u00c7al\u0131\u015fmalarda Sotorasib: Ger\u00e7ek Hayatta Ne Kadar Etkili?<\/h2>\n<p>\nSotorasib, \u00f6zellikle <strong>KRAS G12C pozitif, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK)<\/strong> hastalar\u0131nda dikkat \u00e7ekici klinik sonu\u00e7lar verdi. CodeBreaK 100 faz I\u2013II \u00e7al\u0131\u015fmas\u0131nda:\n<\/p>\n<ul>\n<li><strong>Objektif yan\u0131t oran\u0131 (ORR)<\/strong> yakla\u015f\u0131k %37,<\/li>\n<li>Hastalar\u0131n yakla\u015f\u0131k %80\u2019inde t\u00fcm\u00f6r hacminde k\u00fc\u00e7\u00fclme,<\/li>\n<li><strong>Medyan progresyonsuz sa\u011fkal\u0131m (PFS)<\/strong> ise 6,8 ay civar\u0131nda raporland\u0131<br \/>\n  <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1917239\">doi:10.1056\/NEJMoa1917239<\/a>.<\/li>\n<\/ul>\n<p>\nArd\u0131ndan gelen faz III <strong>CodeBreaK 200<\/strong> \u00e7al\u0131\u015fmas\u0131nda sotorasib, standart ikinci basamak tedavilerden biri olan <strong>doketaksel<\/strong> ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131 ve PFS a\u00e7\u0131s\u0131ndan anlaml\u0131 \u00fcst\u00fcnl\u00fck sa\u011flad\u0131<br \/>\n<a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2210438\">doi:10.1056\/NEJMoa2210438<\/a>. Bu sonu\u00e7lar, sotorasib\u2019i KRAS G12C mutasyonlu KHDAK i\u00e7in tedavi algoritmalar\u0131nda g\u00fc\u00e7l\u00fc bir se\u00e7enek haline getirdi.\n<\/p>\n<h2>Sotorasib Yan Etkileri: Hedefe Y\u00f6nelik Ama Tamamen Masum De\u011fil<\/h2>\n<p>\nSotorasib, klasik sitotoksik kemoterapilere k\u0131yasla genellikle <strong>daha tolere edilebilir<\/strong> bir yan etki profiline sahip olsa da dikkat gerektiriyor. En s\u0131k bildirilen yan etkiler:\n<\/p>\n<ul>\n<li>\u0130shal<\/li>\n<li>Bulant\u0131<\/li>\n<li>Yorgunluk<\/li>\n<li><strong>Karaci\u011fer enzimlerinde (ALT\/AST) y\u00fckselme<\/strong><\/li>\n<\/ul>\n<p>\nDaha nadir ancak klinik olarak \u00f6nemli reaksiyonlar aras\u0131nda:\n<\/p>\n<ul>\n<li>\u0130la\u00e7 ili\u015fkili <strong>hepatotoksisite<\/strong>,<\/li>\n<li><strong>\u0130nterstisyel akci\u011fer hastal\u0131\u011f\u0131 \/ pn\u00f6monit<\/strong> yer al\u0131yor<br \/>\n  <a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(21)00036-5\">doi:10.1016\/S1470-2045(21)00036-5<\/a>.<\/li>\n<\/ul>\n<p>\nBu nedenle, sotorasib tedavisi s\u0131ras\u0131nda:\n<\/p>\n<ul>\n<li><strong>Karaci\u011fer fonksiyon testlerinin d\u00fczenli izlenmesi,<\/strong><\/li>\n<li>Yeni ba\u015flayan \u00f6ks\u00fcr\u00fck, nefes darl\u0131\u011f\u0131 gibi solunum semptomlar\u0131n\u0131n yak\u0131ndan takip edilmesi<\/li>\n<\/ul>\n<p>\nklinik pratikte b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor.\n<\/p>\n<h2>Diren\u00e7 Mekanizmalar\u0131 ve Gelecek: Sotorasib Kombinasyonlar\u0131 Yolda<\/h2>\n<p>\nT\u00fcm hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7larda oldu\u011fu gibi, sotorasib tedavisinde de zamanla <strong>edinilmi\u015f diren\u00e7<\/strong> ortaya \u00e7\u0131kabiliyor. Bildirilen ba\u015fl\u0131ca diren\u00e7 mekanizmalar\u0131:\n<\/p>\n<ul>\n<li>\u0130kincil KRAS mutasyonlar\u0131,<\/li>\n<li><strong>MET<\/strong> veya <strong>EGFR<\/strong> gibi bypass sinyal yollar\u0131n\u0131n aktivasyonu,<\/li>\n<li>T\u00fcm\u00f6r mikro\u00e7evresinde adaptif de\u011fi\u015fiklikler<br \/>\n  <a href=\"https:\/\/doi.org\/10.1038\/s43018-021-00227-1\">doi:10.1038\/s43018-021-00227-1<\/a>.<\/li>\n<\/ul>\n<p>\nBu nedenle g\u00fcncel ara\u015ft\u0131rmalar, sotorasib\u2019in \u015fu ajanlarla kombinasyonunu yo\u011fun bi\u00e7imde inceliyor:\n<\/p>\n<ul>\n<li><strong>EGFR veya MET inhibit\u00f6rleri<\/strong> ile \u00e7ift blokaj,<\/li>\n<li><strong>MEK inhibit\u00f6rleri<\/strong> ile a\u015fa\u011f\u0131 ak\u0131m yol bask\u0131lanmas\u0131,<\/li>\n<li><strong>PD-1\/PD-L1 imm\u00fcnoterapi<\/strong> ajanlar\u0131 ile sinyal yolu + imm\u00fcn sistem sinerjisi.<\/li>\n<\/ul>\n<p>\n\u00d6zellikle kolorektal ve pankreas kanserlerinde, sotorasib\u2019in tek ba\u015f\u0131na yan\u0131t oranlar\u0131 akci\u011fer kanserine g\u00f6re daha d\u00fc\u015f\u00fck bulunmu\u015f olsa da, kombinasyon stratejileriyle daha kal\u0131c\u0131 ve derin yan\u0131tlar elde etme potansiyeli dikkat \u00e7ekiyor<br \/>\n<a href=\"https:\/\/doi.org\/10.1038\/s41591-020-0845-2\">doi:10.1038\/s41591-020-0845-2<\/a>.\n<\/p>\n<h2>Sonu\u00e7: K\u00fc\u00e7\u00fck Molek\u00fcl Sotorasib, \u201c\u0130la\u00e7lanamaz\u201d Hedefleri Yeniden Tan\u0131ml\u0131yor<\/h2>\n<p>\n<strong>Sotorasib<\/strong>, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131 ve hedefe y\u00f6nelik akci\u011fer kanseri tedavisi alan\u0131nda paradigmay\u0131 de\u011fi\u015ftiren bir \u00f6rnek olarak \u00f6ne \u00e7\u0131k\u0131yor. KRAS G12C mutasyonunu kovalent ve se\u00e7ici bi\u00e7imde hedefleyebilmesi, hem klinik onkoloji hem de ila\u00e7 ke\u015ffi ekosistemi i\u00e7in <strong>yeni bir d\u00f6nemin kap\u0131s\u0131n\u0131 aral\u0131yor<\/strong>. \u00d6n\u00fcm\u00fczdeki y\u0131llarda, daha g\u00fc\u00e7l\u00fc ikinci nesil KRAS inhibit\u00f6rleri ve ak\u0131ll\u0131 kombinasyon rejimleriyle, bu k\u00fc\u00e7\u00fck molek\u00fcl y\u0131ld\u0131z\u0131n etkisini daha da fazla konu\u015faca\u011f\u0131z gibi g\u00f6r\u00fcn\u00fcyor.\n<\/p>\n<h2>S\u0131k Sorulan Sorular (SSS)<\/h2>\n<h3>1. Sotorasib hangi hastalarda kullan\u0131l\u0131r?<\/h3>\n<p>\nSotorasib, <strong>KRAS G12C mutasyonu ta\u015f\u0131yan, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK)<\/strong> hastalar\u0131nda, genellikle \u00f6nceki sistemik tedavilerden sonra kullan\u0131lan hedefe y\u00f6nelik bir k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7t\u0131r<br \/>\n<a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1917239\">doi:10.1056\/NEJMoa1917239<\/a>.\n<\/p>\n<h3>2. Sotorasib bir kemoterapi ilac\u0131 m\u0131?<\/h3>\n<p>\nHay\u0131r. Sotorasib klasik sitotoksik kemoterapi de\u011fildir. <strong>Hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl KRAS G12C inhibit\u00f6r\u00fcd\u00fcr<\/strong>. Mutant proteine \u00f6zg\u00fc ba\u011flanma mekanizmas\u0131 sayesinde daha se\u00e7ici etki g\u00f6sterir ve genellikle kemoterapiye g\u00f6re farkl\u0131 bir yan etki profiline sahiptir.\n<\/p>\n<h3>3. Sotorasib ile tedavi ne kadar s\u00fcrer?<\/h3>\n<p>\nTedavi s\u00fcresi sabit de\u011fildir. Hasta ilac\u0131 tolere etti\u011fi ve g\u00f6r\u00fcnt\u00fcleme ile <strong>t\u00fcm\u00f6r progresyonu saptanmad\u0131\u011f\u0131<\/strong> s\u00fcrece tedavi devam eder. S\u00fcre, klinik yan\u0131t, yan etki profili ve hastan\u0131n genel durumuna g\u00f6re bireyselle\u015ftirilir<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(21)00036-5\">doi:10.1016\/S1470-2045(21)00036-5<\/a>.\n<\/p>\n<h3>4. KRAS G12C mutasyonu nas\u0131l tespit edilir?<\/h3>\n<p>\nKRAS G12C mutasyonu, t\u00fcm\u00f6r dokusu biyopsisi veya dola\u015f\u0131mdaki t\u00fcm\u00f6r DNA\u2019s\u0131 (ctDNA) \u00fczerinden yap\u0131lan <strong>NGS panelleri<\/strong> ya da hedefe y\u00f6nelik molek\u00fcler testlerle saptan\u0131r. Sotorasib tedavisine ba\u015flamadan \u00f6nce bu mutasyonun varl\u0131\u011f\u0131n\u0131n do\u011frulanmas\u0131 zorunludur.\n<\/p>\n<h3>5. Sotorasib sadece akci\u011fer kanserinde mi kullan\u0131l\u0131yor?<\/h3>\n<p>\nSotorasib, ba\u015fta <strong>akci\u011fer adenokarsinomu<\/strong> olmak \u00fczere KRAS G12C pozitif t\u00fcm\u00f6rlerde ara\u015ft\u0131r\u0131l\u0131yor. Kolorektal ve pankreas kanserlerinde de k\u0131smi yan\u0131tlar bildirilmi\u015f olsa da, bu t\u00fcm\u00f6rlerde yan\u0131t oranlar\u0131 daha d\u00fc\u015f\u00fck ve genellikle <strong>kombinasyon tedavileri<\/strong> g\u00fcndemde<br \/>\n<a href=\"https:\/\/doi.org\/10.1038\/s41591-020-0845-2\">doi:10.1038\/s41591-020-0845-2<\/a>.\n<\/p>\n<h2>Kaynaklar (DOI)<\/h2>\n<ul>\n<li>10.1056\/NEJMoa1917239<\/li>\n<li>10.1056\/NEJMoa2210438<\/li>\n<li>10.1038\/s41586-020-3185-5<\/li>\n<li>10.1016\/S1470-2045(21)00036-5<\/li>\n<li>10.1038\/s43018-021-00227-1<\/li>\n<li>10.1038\/s41591-020-0845-2<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>KRAS G12C mutasyonu nedir, akci\u011fer adenokarsinomunda neden kritiktir ve ilk se\u00e7ici KRAS G12C inhibit\u00f6rlerinden sotorasib nas\u0131l \u00e7al\u0131\u015f\u0131r? Mekanizmas\u0131, klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131 ve akci\u011fer kanseri tedavisindeki yeri hakk\u0131nda detayl\u0131 bilgi.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[813,814,811,800,812],"class_list":["post-10257","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-akciger-kanseri","tag-hedefe-yonelik-tedavi","tag-kras-g12c","tag-kucuk-hucreli-disi-akciger-kanseri","tag-sotorasib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10257"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10257\/revisions"}],"predecessor-version":[{"id":10258,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10257\/revisions\/10258"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}